Press coverage about Biohaven Pharmaceutical (NYSE:BHVN) has trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Biohaven Pharmaceutical earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.1510914385342 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Several equities research analysts have recently issued reports on the company. BidaskClub lowered Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Thursday, October 5th. Piper Jaffray Companies reissued a “buy” rating and set a $54.00 price target on shares of Biohaven Pharmaceutical in a research note on Tuesday, September 12th. Zacks Investment Research raised Biohaven Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday, October 17th. William Blair reissued an “outperform” rating on shares of Biohaven Pharmaceutical in a research note on Tuesday, October 3rd. Finally, Needham & Company LLC decreased their price target on Biohaven Pharmaceutical from $43.00 to $36.00 and set a “buy” rating for the company in a research note on Tuesday, October 3rd. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $37.17.
Shares of Biohaven Pharmaceutical (NYSE:BHVN) opened at $21.77 on Wednesday. Biohaven Pharmaceutical has a 1 year low of $17.00 and a 1 year high of $39.51.
In related news, VP Kimberly Gentile sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $29.28, for a total transaction of $146,400.00. Following the transaction, the vice president now directly owns 5,000 shares in the company, valued at approximately $146,400. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Vlad Coric sold 150,000 shares of the business’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $29.41, for a total value of $4,411,500.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 439,131 shares of company stock valued at $12,011,701.
TRADEMARK VIOLATION NOTICE: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/13/biohaven-pharmaceutical-bhvn-earning-somewhat-positive-press-coverage-study-finds.html.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.